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METHODOLOGY Open Access
Evaluation of a multi-marker immunomagnetic
enrichment assay for the quantification of
circulating melanoma cells
James B Freeman1, Elin S Gray1, Michael Millward2, Robert Pearce1 and Melanie Ziman1,3,4*
Abstract
Background: Circulating melanoma cells (CMCs) are thought to be valuable in improving measures of prognosis in
melanoma patients and may be a useful marker of residual disease to identify non-metastatic patients requiring
adjuvant therapy. We investigated whether immunomagnetic enrichment targeting multiple markers allows more
efficient enrichment of CMCs from patient peripheral blood than targeting a single marker. Furthermore, we aimed
to determine whether the number of CMCs in patient blood was associated with disease stage.
Methods: We captured CMCs by targeting the melanoma associated markers MCSP and MCAM as well as the
melanoma stem cell markers ABCB5 and CD271, both individually and in combination, by immunomagnetic
enrichment. CMCs were enriched and quantified from the peripheral blood of 10 non-metastatic and 13 metastatic
melanoma patients.
Results: Targeting all markers in combination resulted in the enrichment of more CMCs than when any individual
marker was targeted (p < 0.001-0.028). Furthermore, when a combination of markers was targeted, a greater
number of CMCs were enriched in metastatic patients compared with non-metastatic patients (p = 0.007).
Conclusions: Our results demonstrated that a combination of markers should be targeted for optimal isolation of
CMCs. In addition, there are significantly more CMCs in metastatic patients compared with non-metastatic patients
and therefore quantification of CMCs may prove to be a useful marker of disease progression.
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Background
Melanoma is an aggressive and drug resistant skin can-
cer which is responsible for 80% of skin cancer related
deaths [1]. Current prognostic techniques are inadequate
for disease management as many patients considered
clinically disease free following primary tumour resec-
tion later develop metastases. This is highlighted by the
10 year survival rate for non-metastatic patients, which
ranges from 39% to 93%, depending on the primary
tumour thickness, mitotic rate and presence of ulcer-
ation [2]. There is no measure of residual disease in early
stage patients post surgery and those requiring treat-
ment are consequently unable to be identified. More
sensitive measures need to be developed in order to
more accurately stage patients and assist identification
of early stage patients at risk of developing metastatic
disease [3-5].
It is thought that the number of circulating melanoma
cells (CMCs) in patient peripheral blood may be a useful
prognostic marker [6-8]. The presence of circulating
tumour cells is correlated with prognosis in breast, pros-
tate and colorectal cancer patients [9-18]. CMCs can be
detected by reverse transcription polymerase chain reac-
tion (RT-PCR) and results have shown detection of melan-
oma markers correlates with poor prognosis [1,3,19-22].
Furthermore, RT-PCR has demonstrated expression of
melanoma markers in peripheral blood of early stage
patients with no clinical evidence of metastasis, suggesting
CMCs are present in all disease stages [3,20,21]. The use
of RT-PCR does not allow CMCs to be quantified,
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however, there has been promise shown by immunomag-
netic enrichment, where magnetic particles conjugated to
antibodies specific for melanoma antigens are used to
isolate CMCs from patient blood [8,23-26].
Melanoma chondroitin sulfate proteoglycan (MCSP) is
highly expressed in more than 85% of melanomas [25],
irrespective of disease stage. Anti-MCSP antibodies have
been commonly used to isolate CMCs through positive
immunomagnetic enrichment [8,25,27] as well as for
identification of CMCs by flow cytometry [26,28]. Ex-
pression of melanoma cell adhesion molecule (MCAM)
is associated with an aggressive, invasive phenotype and
upregulation is linked with disease progression [29-31].
Therefore, anti-MCAM might allow the isolation of
CMCs exhibiting an aggressive phenotype which may
have greater metastatic potential.
There has been recent discussion regarding the pres-
ence of stem-like tumour initiating cells in melanoma.
Some research has shown that these cells may be re-
sponsible for tumour maintenance and renewal and may
account for the fact that melanoma is notoriously diffi-
cult to treat. ATP-binding cassette sub-family B member
5 (ABCB5) and CD271 have been shown to be asso-
ciated with a melanoma initiating cell phenotype.
ABCB5 has been shown to be expressed in a subset of
melanoma cells and is associated with tumour forma-
tion, metastasis and resistance to treatment [32-35].
CD271 expression has similarly been associated with
increased capability to initiate tumour formation and
metastasise [36]. ABCB5 and CD271 may be useful mar-
kers for targeting tumour initiating CMCs.
Here we conducted a pilot study to enrich and quan-
tify CMCs from patient blood by targeting the MCSP,
MCAM, ABCB5 and CD271 antigens with antibody
coupled immunomagnetic beads. We evaluated the sen-
sitivity of CMC isolation by enrichment with each indi-
vidual bead type versus a combination of beads and
compared the number of CMCs enriched between early
stage, non-metastatic, and late stage, metastatic, melan-
oma patients.
Methods
Cell lines and antibodies
A2058 metastatic melanoma cells and human embryonic
kidney 293 (HEK293) cells were cultured in DMEM sup-
plemented with 10% foetal bovine serum (FBS).
Mouse anti-human monoclonal antibodies to MCAM
(clone P1H12), MCSP (clone 9.2.27), CD271 (clone C40-
1457) and CD45 (clone HI30) were purchased from BD
Biosciences (San Jose, CA, USA). Rabbit anti-human
polyclonal antibody to ABCB5 (clone RB16781) was pur-
chased from Abgent (San Diego, CA, USA). Secondary
antibodies were anti-mouse and anti-rabbit conjugated
to Alexa-Fluor 488 (A488) and biotinylated anti-mouse,
which was used with streptavidin-A488.
Patient blood samples
Patients, recruited from 3 clinics in Perth, Australia,
were diagnosed and staged according to guidelines of
the American Joint Committee on Cancer (AJCC). All
patients recruited between August 2011 and March
2012 were included in the study. Peripheral blood sam-
ples were obtained from 10 non-metastatic (stage I and II)
and 13 metastatic (stage III and IV) patients. Additionally,
15 control blood samples were obtained from healthy
volunteers. Blood was drawn by phlebotomists into
EDTA tubes, after the first few millilitres was discarded
to avoid epithelial contamination, and refrigerated until
use. For 21 of 23 patients, blood was collected into five
EDTA tubes; only one tube was collected for the
remaining two patients and all controls. Patient samples
ranged from 4 to 10 ml and control samples were
9 ml. All results were therefore calculated per ml of
whole blood. Participants signed informed consent with
the clinician in accordance with protocols safeguarding
patient rights. All procedures have been accepted by the
Human Research Ethics Committees at ECU (No. 2932)
and SCGH (No. 2007–123).
Immunofluorescence
Expression of MCAM, MCSP, ABCB5, CD271 and CD45
was tested in A2058 and HEK293 cells by immunofluores-
cence. Approximately 60,000 cells were seeded per cover-
slip and allowed to adhere overnight. Attached cells were
fixed with 4% paraformaldehyde for 10 minutes at room
temperature and stained with primary antibody, diluted in
PBS with 3% BSA for one hour at room temperature.
MCAM, MCSP and CD45 antibodies were diluted 1/500,
ABCB5 1/250 and CD271 1/750. Cells were then stained
with secondary antibody, diluted 1/500, for 20 minutes at
room temperature. Cells were washed three times with PBS
between each step. Coverslips were mounted onto micro-
scope slides with ProLong Gold anti-fade mounting
medium containing DAPI for nuclear staining (Invitrogen,
Carlsbad, CA, USA) before analysis with an Olympus BX51
microscope equipped with an Olympus DP71 camera.
Antibody-bead coupling
MCSP, MCAM, ABCB5 and CD271 antibodies were co-
valently bound to magnetic beads using the Dynabeads
Antibody Coupling Kit (Invitrogen), as per the manufac-
turer’s instructions. For efficient antibody-bead coupling,
10 μg of antibody was used per mg of Dynabeads.
Binding capacity of antibody coupled beads
A2058 cells were harvested in DMEM containing 5 mM
EDTA and analysed with the Vi-Cell-XR Cell Viability
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Analyser (Beckman Coulter, Brea, CA, USA). 0.5 × 106
A2058 cells were added to six tubes. 0.5 μl of MCSP
beads was added to three tubes and 0.5 μl of MCAM
beads was added to the remaining three tubes. Tubes
were incubated for one hour at 4°C with rotation and sub-
sequently placed on a DynaMag-2 magnet (Invitrogen).
Enriched cells were washed three times with PBS, resus-
pended in 500 μl of PBS and counted with the Vi-Cell-XR
Cell Viability Analyser. 0.5 μl of MCSP beads bound a
mean of 1.42× 105 cells and 0.5 μl of MCAM beads bound
a mean of 0.98× 105 cells.
Quantification of spiked melanoma cells and patient
CMCs
A2058 cells were harvested as previously described. Only
cells with greater than 90% viability were used. Cells
were spiked into DMEM/10% FBS or white blood cells
(WBCs) resuspended in 1 ml incubation buffer (0.5%
BSA, 2 mM EDTA in PBS, pH 7.2), following lysis of
control blood with lysis buffer (140 mM NH4Cl, 17 mM
Tris, pH 7.65). Spikes of 1, 10 and 20 cells were per-
formed by pippetting under a microscope, while 50 and
100 cell spikes were performed by dilution. Cells were
incubated with 0.5 μl of MCSP beads or a combination
of MCSP, MCAM, ABCB5 and CD271 beads (with a
combined volume of 0.5 μl) for one hour at 4°C with ro-
tation. Enriched cells were placed on a DynaMag-2 mag-
net (Invitrogen), washed three times with PBS and
mounted on microscope slides as previously described.
Before mounting, cells enriched from control blood were
fixed with 4% paraformaldehyde for 10 minutes at room
temperature, stained with CD45 antibody (diluted 1/500
in PBS containing 3% BSA) for one hour at room
temperature, followed by biotinylated anti-mouse and
streptavidin-A488, both for 10 minutes at room
temperature. Two PBS washes were performed between
each antibody incubation. Enriched cells were quantified
by microscopy where WBCs were defined as CD45 posi-
tive and melanoma cells as CD45 negative.
Control and patient blood was processed within
24 hours of collection. Blood was lysed as previously
described. For controls and patients, one blood sample
was incubated with a combination of MCSP, MCAM,
ABCB5 and CD271 beads (combined volume 0.5 μl).
The four remaining patient samples were incubated with
0.5 μl of one of the four individual bead types. Samples
were incubated, washed and stained as previously
described and quantified by microscopy.
DNA amplification and detection of B-raf V600E mutation
Enriched cells attached to magnetic beads were lysed for
whole genome amplification using the Repli-g kit (Qiagen,
Germantown, MD, USA). In summary, after two PBS
washes, all buffer was removed and cells attached to
the magnetic beads were resuspended in 3.5 μl of cell
lysis buffer containing DTT, incubated 10 minutes at
room temperature then stop solution was added.
Whole genome amplification was carried out as per
the manufacturer’s instructions.
The V600E mutation was detected using the qBiomarker
Somatic Mutation PCR Assay (c.1799 T>A) relative to a
reference PCR for the B-raf gene (SABiosciences, Qiagen).
Quantitative PCR was performed in a ViiA 7 Real-Time
System (Applied Biosystems, Foster City, CA, USA).
Statistics
Statistical tests were performed using SPSS Statistics 19
(IBM). The Mann–Whitney U Test was used to compare
the number of CMCs between patients and controls and
between metastatic and non-metastatic patients. The
Wilcoxon Signed Rank test was used to compare the
number of CMCs enriched with a combination of beads
versus each individual bead type. P < 0.05 was considered
statistically significant. The two patients with missing
data were excluded from the appropriate analyses.
Results
Expression of markers in cell lines by
immunofluorescence
Expression of MCAM, MCSP, ABCB5, CD271 and CD45
was demonstrated in A2058 melanoma cells by immuno-
fluorescence. HEK293 cells, used as negative controls,
were 100% negative when stained with each antibody
(not shown). A2058 cells were 100% positive for MCSP
and MCAM (Figure 1a and Figure 1b respectively), while
ABCB5 and CD271 were expressed on <1% of A2058
cells (Figure 1c and Figure 1d respectively), suggesting
the presence of rare subpopulations within the cell line.
A2058 cells were 100% negative when stained with CD45
(Figure 1e) and secondary antibody only (Figure 1f ). This
result supports the use of MCSP and MCAM to enrich
the general CMC population. ABCB5 and CD271 appear
useful for isolating rare CMC subsets.
Sensitivity and specificity by retrieval of spiked A2058
cells
To compare the sensitivity and specificity of enrich-
ment targeting a single marker versus multiple mar-
kers (Figure 2) an increasing number of A2058 cells (1, 10,
20, 50 and 100) were spiked into media (DMEM/10% FBS)
or control blood in triplicate and enriched with MCSP
beads or a combination of all beads.
Percentage retrieval of cells spiked into media was
high (mean = 76.7%). However, retrieval of cells from
control blood was much less sensitive (mean = 35.8%),
presumably due to the low specificity of the beads. This
is supported by the observation of a large number of
CD45 positive cells in the enriched fraction. Increasing
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the volume of beads increased the amount of non-
specific binding but did not improve the recovery of
spiked A2058 cells.
The highest percentage recovery was observed in single
cell spikes (Figure 2), however it should be noted that
CD45 negative cells were counted as recovered A2058
cells in blood. As we occasionally observed single CD45
negative cells in control blood (Figure 3b), a CD45 nega-
tive cell enriched from a single cell spike may not always
be an A2058 cell and may account for the increased
percentage recovery of single A2058 cells from blood.
There was little difference between recoveries of spiked
cells using MCSP beads alone versus a combination of
beads. However, given our observation that 100% of A2058
cells are MCSP positive, the benefit of a combination of
beads may not be apparent in the recovery of spiked cells
as much as it may improve the recovery of CMCs from pa-
tient blood, where CMC phenotype is unknown.
In order to improve the sensitivity and specificity of the
assay we tested the indirect method of immunomagnetic
enrichment, where cells are first labelled with primary anti-
body and subsequently enriched with antibody-specific
beads. We enriched spiked A2058 cells from control blood
using the Dynabeads CELLection Pan Mouse IgG Kit
(Invitrogen) according to the manufacturer’s instruc-
tions. While non-specific enrichment was decreased,
the percentage of spiked cells recovered was also
reduced (data not shown).
Detection of CMCs in patient and control blood
CMCs were enriched from 15 control and 23 patient
blood samples with a combination of MCSP, MCAM,
Figure 1 Immunofluorescent analysis of A2058 melanoma cells. A2058 cells were 100% positive for both MCSP (a) and MCAM (b). Less than
1% of cells were positive for both ABCB5 (c) and CD271 (d). All A2058 cells were CD45 negative (e). Anti-mouse A488-conjugate secondary
antibody only staining was used as negative control and 100% of cells were negative (f). All images are an overlay of blue (DAPI) and green
fluorescence (specific marker), with the same exposure for green fluorescence. Original magnification 400x. Scale bars, 100 μm.
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ABCB5 and CD271 beads. In order to exclude non-
specifically bound blood cells, enriched cells were stained
for CD45, which is expressed on all human leukocytes
[37]. Positively enriched CD45 negative cells were consid-
ered CMCs (Figure 4). A maximum of one CMC, or 0.11
CMCs per ml of whole blood, was detected in control
blood samples. More than one CMC was detected in
73.9% of patients and ranged from 0 to 2.5 CMCs per ml
(Figure 3b). There were significantly more CMCs per ml
of whole blood in patients than controls (p < 0.001,
Mann–Whitney U-Test). It is important to note that a
maximum of one CMC was detected in 9 ml of blood
in 4 of the 15 control samples. By contrast, increased
numbers of CMCs were detected in patient samples even
when lower volumes, usually 4 or 6 ml, were analysed.
Although positive enrichment has been shown to result
in higher purity than negative enrichment [26], we still
observed low purity of CMCs (data not shown). We trialled
a CD45 depletion step before positive enrichment to in-
crease the purity of enriched CMCs, however, our results
showed that CD45 depletion did not reduce the number of
non-specifically enriched leukocytes (data not shown).
Detection of V600E mutation in CMC enriched cells
An increasing number of A2058 cells (1, 5, 10 and 100)
were spiked into control blood. Unspiked blood was
used as a negative control in all experiments. Enriched
cells attached to the beads were lysed and whole genome
amplified. Amplified DNA was used to detect the B-raf
V600E mutation by real-time PCR. A2058 cells are het-
erozygous for the V600E mutation [38]. We were con-
sistently able to detect the mutation when 10 and 100
cells were spiked. However, PCR positivity was only
observed in 30% of cases when 1 or 5 cells were spiked.
This is in line with the percentage retrieval demon-
strated above (Figure 2). It is possible that allele drop-
Figure 3 Number of CMCs per ml whole blood in patients and controls. (a) The number of CMCs per ml whole blood enriched from
patients using MCAM, MCSP, ABCB5 and CD271 beads individually and in combination. (b) The number of CMCs per ml whole blood in healthy
controls (n = 15), non-metastatic patients (stage I & II) (n = 10) and metastatic patients (stage III & IV) (n = 13) using a combination of all beads. The
median and interquartile range of each group are indicated. The p-value of each comparison is denoted over the corresponding capped line.
Figure 2 Recovery of spiked A2058 cells from growth media and control blood with MCSP beads alone versus a combination of all
beads. The number of A2058 cells recovered from media (DMEM with 10% FBS) (dashed lines) was high compared to control blood (solid lines),
as depicted in the graph. The average% recoveries of three independent spiking experiments are shown in the table.
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out, which is a common problem in single-cell PCR [39],
might have occurred in the samples where only one cell
was present, reducing the number of tests positive for
the B-raf V600E mutation in 1 and 5 cell spikes. Never-
theless, our results demonstrated that we were able to
detect the V600E mutation in one cell amid a back-
ground of non-specifically bound leukocytes. The V600E
mutation was further detected in CMCs enriched with a
combination of magnetic beads in 6 of 8 patients tested,
who had confirmed V600E-positive tumours. This result
confirmed the enriched fraction contained tumour
derived cells.
Targeting a combination of markers versus a single
marker for enrichment of CMCs
CMCs were enriched with antibody-coupled beads indi-
vidually and in combination to see whether targeting
multiple markers resulted in enrichment of more CMCs.
Significantly more CMCs were enriched per ml whole
blood when beads were used in combination rather than
individually (MCAM, p = 0.028; MCSP, p = 0.002; ABCB5,
p < 0.001; or CD271, p = 0.001; Wilcoxon Signed-Rank
Test) (Figure 3a).
CMCs in metastatic and non-metastatic patients
To determine whether there was a difference in the num-
ber of CMCs between early and late stage patients,
CMCs were enriched in 10 non-metastatic and 13 meta-
static patients. Significantly more CMCs were enriched
from metastatic patients when a combination of beads
was used (p = 0.007, Mann–Whitney U-Test) (Figure 3b).
There was however no statistically significant difference
when any individual marker was targeted.
Discussion
Melanoma primary and metastatic tumours have highly
heterogeneous expression patterns [20,22,27,40] and it is
likely that CMCs also exhibit this heterogeneity. Thus
here we undertook a novel strategy by targeting a com-
bination of melanoma associated antigens and stem-cell
Figure 4 CMCs enriched from patient blood. (a) CMC (centre) and two CD45 positive WBCs, (b) CMC, (c) & (d) WBCs. The small green
fluorescent spheres are the antibody-coupled beads.
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markers to enrich CMCs from patient blood. Our results
demonstrated that targeting multiple markers resulted in
detection of more CMCs than targeting any individual
marker tested. This suggests that the CMC population is
heterogeneous and may explain why CMCs are detected
in only a small percentage of patients in studies targeting
a single marker. Ulmer et al. (2004) detected CMCs in
26% of melanoma patients across all stages when MCSP
alone was targeted [8]. We propose the multi-marker ap-
proach allowed detection of cells with different pheno-
types. Our finding is in line with research showing
multi-marker RT-PCR assays are more sensitive than
single marker assays [3,21,22,41]. Thus, different combi-
nations of markers should be tested for optimal CMC
enrichment. By targeting multiple cell surface markers
the sensitivity of CMC detection was increased yet the
specificity of the test was not reduced as no more than
one CMC was detected in control blood.
Our spiking experiments showed immunomagnetic
enrichment has low efficiency, as a consistently low per-
centage of spiked cells were recovered from blood. This
result is similar to other studies trialling this technique
[23,26] and suggests there is also low efficiency when
enriching CMCs from patient blood. Thus, we infer that
our assay allows us to detect only a proportion of the
total number of CMCs in patient blood. However, com-
parison between groups is justified as a similar propor-
tion of total CMCs should be detected in all samples.
In this study, CMCs were quantified by negative exclu-
sion of CD45 positive cells, rather than by positive stain-
ing, as there are currently no markers known to be
expressed on all CMCs [42]. Furthermore, we targeted
tumour initiating CMCs that do not always express
common melanoma associated antigens [36] so confirm-
ation by positive staining of markers such as MART-1 or
tyrosinase could result in exclusion of these cells. Posi-
tive staining for MCSP, MCAM, ABCB5 or CD271 was
not feasible due to antigen binding sites being occupied
by the antibody-coated beads.
CMCs were detected in all disease stages, suggesting
cells are shed from primary tumours even early in disease
progression. Some research suggests tumour cells can
reach circulation during early stage disease, providing a
population of dormant CMCs [43-45]. Since a larger num-
ber of CMCs were detected in metastatic patients than
non-metastatic patients, quantification of CMCs may im-
prove measures of disease progression. The presence of
circulating tumour cells is associated with poor prognosis
in early stage uveal melanoma [46] and other metastatic
cancers [10-12,33,47]. Thus detection of CMCs in early
stage patients may be useful for identifying those at risk of
disease progression.
Here we showed the detection of the B-raf V600E mu-
tation in the CMC enriched fraction. Similarly, previous
studies have demonstrated the presence of this activating
mutation in CMCs captured using anti-MCSP antibodies
[25,27]. Furthermore, KRAS and EGFR mutations have
been detected in circulating tumour cells from patients
with metastatic colon and lung cancer respectively
[48,49]. Moreover, serial genotyping of circulating lung
cancer cells during gefitinib therapy demonstrated the
emergence of the kinase inhibitor resistance–associated
mutation T790M at increasing allelic ratios, coinciding
with clinical relapse [48]. Genetic profiling of CMCs
may prove valuable for monitoring the development of
escape mutations during treatment. However, the extent
to which CMCs represent the broader mutation profile
of the parental tumours requires further investigation.
Conclusion
In summary, the use of multiple markers to target CMCs
provides a substantial improvement in sensitivity of isola-
tion compared to previous studies targeting a single mar-
ker. Moreover, the use of multiple antibodies combined
with negative exclusion of enriched cells allowed us to tar-
get rare cell populations. The detection of B-raf V600E
confirms the presence of melanoma cells in the enriched
fraction and supports the use of this methodology for gen-
etic characterisation of CMCs. Our results indicate that
quantification of CMCs may improve measures of disease
progression and could further be used to evaluate treat-
ment efficacy by determining whether CMCs are reduced
following treatment. Additional research to evaluate the
prognostic value of CMCs using this methodology is
warranted where patients are monitored longitudinally
to relate CMC numbers to disease outcome.
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